ArticleFrontiers in nutrition2026
Preoperative exclusive enteral nutrition ameliorates CRP-to-albumin ratio without affecting body mass index in Crohn's disease.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Crohn's disease (CD) frequently exhibits malnutrition and systemic inflammation, both of which are closely linked to elevated surgical risks and postoperative complications. Exclusive enteral nutrition (EEN) is a standard nutritional therapy for CD, yet whether its core mechanism functions via nutritional support to improve body mass index (BMI) or via nutritional treatment to modulate inflammation, altering the C-reactive protein-to-albumin ratio (CAR) remains inadequately understood. Besides its related alterations in computed tomography enterography (CTE) parameters and laparoscopic surgery outcomes also remain important points. Methods: A cohort study was conducted at our Inflammatory Bowel Disease Center, enrolling 89 CD patients undergoing bowel resection. Those patients received EEN for 6 weeks preoperatively. All data were collected from a database. Moreover, cross-sectional imaging metrics were assessed by CTE parameters to further demonstrate the impact brought by EEN. Postoperative complications within 30 days were also recorded. Results: Preoperative EEN treatment significantly increased albumin levels (from 34.4 ± 4.1 g/L at baseline to 38.9 ± 4.5 g/L before surgery, Conclusion: Preoperative EEN in CD patients effectively ameliorates the CAR without prominently affecting BMI. As a targeted anti-inflammatory strategy in the immediate preoperative period, EEN exerts its benefits primarily through rapid modulation of inflammation rather than weight gain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.